Systemic Therapy for Vascular Anomalies and the Emergence of Genotype-Guided Management.

Autor:	Nicholson CL; Division of Pediatric Dermatology, Department of Dermatology, University of Minnesota, 2512 South Seventh Street, Floor 3, Minneapolis, MN, USA., Maguiness SM; Division of Pediatric Dermatology, Department of Dermatology, University of Minnesota, 2512 S 7th st, Minneapolis, MN 55454, USA. Electronic address: smaguine@umn.edu.
Jazyk:	angličtina
Zdroj:	Dermatologic clinics [Dermatol Clin] 2022 Apr; Vol. 40 (2), pp. 127-136. Date of Electronic Publication: 2022 Mar 04.
DOI:	10.1016/j.det.2021.12.009
Abstrakt:	Improved understanding of the genetic basis of vascular anomalies has uncovered a growing need for targeted medical therapies. This is especially important for lesions not amenable to surgical interventions or interventional radiologic techniques. Recent studies and case reports have documented the effective use of tailored medical therapies in several distinct types of vascular anomalies. Sirolimus, mitogen-activated protein kinase inhibitors, and phosphoinositide 3-kinase inhibitors have emerged as potential therapies. Although this remains a growing field with significant knowledge gaps, a more optimistic outlook for patients with previously devastating impact on function and quality of life seems now within reach. Competing Interests: Disclosure Dr S.M. Maguiness has participated in an advisory board for Verrica Pharmaceuticals and has been an investigator for Regeneron Sanofi. She is the co-founder of Stryke Club, a personal care brand for teen boys. (Copyright © 2022 Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu